Antimicrobial Susceptibility and Clonal Relationship of Tetracycline Resistance Genes in netF-Positive Clostridium perfringens
NetF-producing type A Clostridium perfringens , a pathotype of C. perfringens , causes necrotizing enteritis in neonatal foals and necrotizing and hemorrhagic enteritis in dogs. Recent core genome multilocus sequence typing study revealed that netF + C. perfringens strains belong to two distinct clo...
Gespeichert in:
Veröffentlicht in: | Microbial drug resistance (Larchmont, N.Y.) N.Y.), 2019-05, Vol.25 (4), p.627-630 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | NetF-producing type A
Clostridium perfringens
, a pathotype of
C. perfringens
, causes necrotizing enteritis in neonatal foals and necrotizing and hemorrhagic enteritis in dogs. Recent core genome multilocus sequence typing study revealed that
netF
+
C. perfringens
strains belong to two distinct clonal populations (clonal complexes I and II). There are no reports on susceptibility to antimicrobial drugs of isolates from this pathotype. The susceptibility to 13 different antimicrobial drugs of 49
netF
+
strains recovered from foals or dogs with necrotizing enteritis in Canada, the United States, and Switzerland was assessed using a commercial microdilution panel designed for anaerobic human pathogens. All isolates were highly susceptible to 12 antimicrobial agents, including all beta-lactams tested, such as penicillin G and ampicillin, as well as clindamycin, chloramphenicol, and metronidazole. The isolates consistently presented a reduced susceptibility or resistance to tetracycline, which was associated with previously described tetracycline resistance genes. Clonal complex I isolates (
n
= 41) possessed the
tetA408
(P) gene, whereas clonal complex II isolates (
n
= 8) possessed the
tetA
(P)-
tetB
(P) genes and were more likely to be fully resistant. |
---|---|
ISSN: | 1076-6294 1931-8448 |
DOI: | 10.1089/mdr.2018.0341 |